The N-methyl-D-aspartate (NMDA) class ionotropic receptors for glutamate play a central role in excitatory neurotransmission in the central nervous system (CNS). Some CNS disorders such as ischemic, hypoxic, hypoglycemic, and traumatic insults, epilepsy, AIDS, dementia, and Huntington's and Alzheimer's diseases are accompanied by disorders of the NMDA receptors. [1] [2] [3] [4] [5] [6] [7] [8] For non-invasive diagnoses of NMDA receptor dysfunctions by PET (positron emission tomography), a number of radioactive ligands labelled with short-lived 18 F (t 1/2 ϭ109.7 min) or 11 C (t 1/2 ϭ20.3 min) have been investigated. However, efforts have been limited by poor brain entry or high levels of nonspecifc binding. 9) Native NMDA receptors are present as complexes containing at least one NR1 subunit and one or more of the four distinct NR2 subunits (NR2A-D), with a number of recognition sites for endo-and exogeneous ligands that modulate neuronal responses. 10, 11) Recently, a series of bis(phenylalkyl)amines (1), structural analogues of ifenprodil, were reported as polyamine site antagonists with high-selectivity for NR2B containing NMDA receptors, as exemplified by compound (1) (Fig. 1, mϭ5 , nϭ2, IC 50 ϭ8 nM for the NR1A/2B subunit combination). [12] [13] [14] [15] There are at least three independent polyamine-binding sites on the NMDA receptors-the glycine-dependent modulatory site, the glycine-independent modulatory site, and the voltage-dependent ion channel site. [16] [17] [18] [19] [20] [21] [22] The bis(phenylalkyl)amines have been shown to bind to the glycine-independent polyamine modulatory site, which is absolutely required for the NR2B subunit. 23) It has been reported that the primary determinants of potency of the bis(phenylalkyl)amines (1) at the NR1A/2B NMDA receptors are (1) the phenolic OH group; (2) the distance between the two aromatic rings; and (3) the nitrogen atom. 15) Thus, we designed mono [ 11 C]methoxyl derivatives of 1. In this study, we synthesized two 11 C-labelled analogues of bis(phenylalkyl)amine, bis(phenylpropyl)amine ([ 
MATERIALS AND METHODS
Radioactivity was quantified with a IGC-3R Curiemeter (Aloka). High-pressure liquid chromatography (HPLC) was done using a JASCO HPLC system for radioactive runs. Effluent radioactivity from the HPLC was determined using a NaI(Tl) scintillation detector system. Carbon-11 was generated by the 14 N(p,a) 11 C nuclear reaction using a CYPRIS-HM-18 Cyclotron (Sumitomo Heavy Industries, Ltd). All animal studies were carried out in compliance with the Animal Ethical Committee of the National Institute of Radiological Sciences and Japanese law. The preparation of [ 11 C]CH 3 I and subsequent 11 C-methylations were carried out automatically by using a synthetic apparatus for 11 C-labelled compounds developed by Suzuki et al.
24) 1
H-NMR spectra were obtained on a JNM GX-270 spectrometer with TMS as an internal standard, and IR spectra were recorded with a JASCO IR Report 100 spectrometer. Low-resolution FAB mass spectra were obtained on a JEOL JMS-D300 spectrometer, and highresolution FAB (HR-FAB-MS) mass spectra were obtained on a JEOL NMS-SX 102-SX spectrometer. Column chromatography was done on a Merck Kieselgel 60 (70-230 mesh) or Fuji gel FL-60D. Thin-layer chromatography (TLC) was carried out on Merck Kieselgel 60 F 254 plates. Melting points were determined on a Yanagimoto melting point apparatus and are uncorrected. Elemental analyses were performed by the staff of the micro-analysis section of Kyushu University.
Synthesis
All chemicals were used without further purification unless otherwise stated. Three polyamine (spermine, spermidine, putrescine) hydrochlorides, L-glutamic acid hydrochloride, glycine, ifenprodil tartrate, 5,7-dichlorokynurenic acid (DCKA), CGS-19755, 8-OH-DPAT hydrobromide, prazosin hydrochloride and ketanserin tartrate, were purchased from Sigma Chemical Co. 1,3-Di-o-tolylguanidine (DTG) was purchased from Aldrich Chemical Co.
Synthesis of 1-p-Toluenesulfonyloxy-3-(4-methoxyphenyl)-propane (4) p-Toluenesulfonyl chloride (6.3 g, 33 mmol) was added to a solution of 3-(4-methoxyphenyl)propanol (5 g, 30 mmol) in anhydrous pyridine (75 ml) at 0°C. The reaction mixture was stirred at 4°C for 16 h, then added to a solution of conc. HCl and ice (1/1, 100 ml). The resulting solution was extracted with Et 2 O (300 ml). The separated organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by chromatography on a silica gel column (hexane : AcOEtϭ5 : 1) to give 4 as a white solid (9. Synthesis of 1-p-Toluenesulfonyloxy-3-(4-methoxyphenyl)-butane (5) p-Toluenesulfonyl chloride (6.1 g, 32 mmol) was added to a solution of 4-(4-methoxyphenyl)butanol (4.7 ml, 27 mmol) in anhydrous pyridine (75 ml) at 0°C. The reaction mixture was stirred at 4°C for 18 h. The work-up and purification were carried out as described above to produce 5 as a colorless oil (7.3 1 mmol) and 60% sodium hydride oil suspension (488 mg, 12.2 mmol) in anhydrous DMF (35 ml) was heated at 40-45°C for 1 h, followed by the addition of 4 (3.5 g, 10.9 mmol) in three portions over 2 h at 50-55°C, and the reaction mixture was stirred at 50-55°C for 1 h. The reaction mixture was diluted with water (35 ml), and extracted with toluene. The separated organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by chromatography on a silica gel column (hexane : AcOEtϭ5 : 1) to give 6 as a white solid ( (35 ml ) was heated at 40-45°C for 1 h, followed by the addition of 5 (3.5 g, 10.5 mmol) in three portions over 2 h at 50-55°C. After the reaction at 50-55°C for 1 h, the reaction mixture was worked up and purified as described above to give 7 as a colorless oil ( 
Synthesis of N,N-Bis(3-(4-hydroxyphenyl)propyl)amine
Hydrobromide (8) A solution of 6 (500 mg, 1.07 mmol) in AcOEt (10 ml) was added to a solution of phenol (10 g, 107 mmol) in 30% HBr/AcOH (194 ml). The reaction mixture was stirred at room temperature for 18 h, then cooled in an ice bath, followed by the addition of water (200 ml Synthesis of N,N-Bis(3-(4-hydroxyphenyl)butyl)amine Hydrobromide (9) A solution of 7 (500 mg, 1.00 mmol) in AcOEt (10 ml) was added to a solution of phenol (10 g, 107 mmol) in 30% HBr/AcOH (194 ml). The reaction mixture was stirred at room temperature for 18 h, worked up and the crude product was purified as described above to give 9 as a brown powder (156.6 mg, 40%): mp 213-217°C; 1 
Synthesis of N-(3-(4-Hydroxyphenyl)propyl)-3-(4-methoxyphenyl)propylamine (2)
The hydrobromide (8) was added to a saturated aqueous solution of NaHCO 3 , and the corresponding free amine was extracted with ether. The organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. Sodium hydride (60% suspension in oil, 2.7 mg, 0.068 mmol) was added to a solution of the above free amine (white powder, 9.5 mg, 0.033 mmol) in anhydrous DMF (1 ml), and the mixture was stirred for 5 min, followed by the addition of methyl iodide (2.1 ml, 0.033 mmol). After the reaction mixture was stirred for 20 min, it was quenched by the addition of 10% aqueous acetic acid, and neutralized with saturated aqueous NaHCO 3 , then extracted with Et 2 O. The separated organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by HPLC (column: nacalai tesque COSMOSIL 5C18-MS, 10ϫ250 mm, 0.05% trifluoroacetic acid in methanol : H 2 Oϭ3 : 2, UV monitor 254 nm, flow rate 4.0 ml/min) to give 2 as a yellow oil (7.3 mg, 74% Synthesis of N-(3-(4-hydroxyphenyl)butyl)-3-(4-methoxyphenyl)butylamine (3) The free amine form was obtained from 9 as described above. Monomethylation of the resulting white powder (7.6 mg, 0.024 mmol) and purification were carried out as described above to give 3 as a yellow oil (2.5 mg, 32% 11 C]3) had been added, the reaction mixture was transferred onto a reverse phase HPLC (column: Waters m-Bondapak C18, 7.8ϫ300 mm) and eluted with the corresponding mobile phases at a flow rate of 3 ml/min. The radioactive peaks corresponding to the desired products (t R ϭca. 10 min for [ 11 C]2, or t R ϭca. 9.5 min for [ 11 C]3) were collected in a flask, respectively. After the solvents were removed under reduced pressure, distilled water or isotonic saline was added to the flask and used for in vitro or in vivo experiments. An aliquot was assayed for radioactivity and checked by HPLC (column: Waters m-Bondapak C18, 3.9ϫ300 mm). The mobile phases were MeOH : 0.05%CF 3 COOHϭ45 : 55 at 0.7 ml/min for [ 11 C]2 and MeOH : 0.05%CF 3 COOHϭ50 : 50 at 0.8 ml/min for [ 11 C]3, respectively. The identity of the products was achieved by HPLC co-injection with authentic 2 or 3. Specific radioactivity at the end of synthesis was calculated by UV spectroscopy. The averages 1.2 GBq of [ In Vitro Binding on Rat Brain Slices Autoradiography on rat brain slices was performed essentially as has been previously described. 25) Brain sagittal cryosections (20 mm) obtained from male Sprague-Dawley rats (10-12 weeks old) were pre-incubated in a 50 mM Tris-HCl buffer (pHϭ7.4) at 25°C for 30 min, followed by incubation in the same buffer containing 2 which are proportional to the radioactivity of the measured sample, 26) and was expressed as region-to-cerebellum ratios calculated by dividing the PSL values in each brain region by the cerebellum PSL value on the same slice. Background PSL values were always subtracted from the total PSL values on ROI. Nonradioactive 2 or 3 (100 mM) were simultaneously incubated with the corresponding radioligand to determine their nonspecific binding. (10, 100 mM, or  1 mM) . Following the incubation, the sections were rinsed, dried and apposed to the imaging plates for 60 min in the same manner as described above. A region of interest (ROI) on the slices was placed on the frontal cortex and the radioactivity in this region was expressed as photostimulated luminescence (PSL) values per mm 2 . The PSL data on the ROI in the presence of drugs were divided by the corresponding control PSL data in the absence of drugs. Background PSL values were subtracted from the total PSL values on ROI. The obtained % control values (defined as 100% for the 11 C-ligand binding activity in the absence of drugs) were averaged in at least triplicate sections from three animals.
Drug Inhibition for in Vitro Binding
In Vivo Brain Distribution [ 11 C]3 (in 0.2 ml water, ca. 55 MBq/ml) was injected via a tail vein into ddY mice (36-38 g). The animals were killed at 10, 30 and 50 min by decapitation. Their whole brains were rapidly removed and dissected into the cerebellum, cerebral cortex, hippocampus, and striatum. A sample of blood was also taken. Radioactivity in each sample was measured with a Packard gammacounter and corrected for decay. The results were expressed as the percentage of injected dose per gram of tissue weight (% dose/g). In separate experiments, the effects of pretreatment of spermine and unlabelled 3 on the brain uptake of male Sprague-Dawley rats (10-12 weeks old) were investigated. The drugs (7 mmol/kg) were injected intravenously 10 min before injection of [ 11 C]3 and the rats were killed at 30 min after the injection of [ 11 C]3. The brain was removed, dissected and regional radioactivity was determined as described above. The control rats were treated with a water solution under identical conditions.
In Vivo Brain Distribution in Monkey An awake-behaving Rhesus monkey (male, 5 kg) was chaired and the head was fixed with a specifically designed head-hold device. All animal PET scans were performed with a high-resolution SHR-7700 PET camera (Hamamatsu Photonics, Shizuoka, Japan) in the same manner as described in the literature. 27) After transmission scans for attenuation correction, a dynamic emission scan in 2D acquisition mode was performed for 90 min (1 minϫ10 scans, 2 minϫ20 scans, 4 minϫ 10 scans) following the injection of [ 11 C]3 (303 MBq, in 2 ml saline) via the crural vein as a single bolus. The emission scan image was reconstructed with a Hanning filter of 4 mm and circular ROIs with a 5-mm diameter were placed over the frontal and occipital cortexes, striatum, and cerebellum. The ROI values were expressed in kBq/ml, normalized to the injected radioactivity of 185 MBq, and plotted against time . A mixture of unlabelled 3 (6 mmol/kg) and [ 11 C]3 (230 MBq) in saline (3 ml) was injected into the same monkey to deter-mine specific binding. The time activity curves in the ROIs were obtained for each scan of the brain.
RESULTS AND DISCUSSION
The synthesis was started with the tosylate (4 or 5), which was reacted with p-toluenesulfonamide in the presence of NaH in DMF to produce a dialkylated product (6 or 7), as described in Chart 1. The methyl protecting groups of 6 and 7 were cleaved by treatment with HBr/AcOH in the presence of phenol to give the diphenols (8, 9), respectively. After neutralization with NaHCO 3 , the free amines of the diphenol compounds (8, 9) were used for the synthesis of 2 and 3, respectively, as well as for the 11 C-methylation. The radiosynthesis of [ 11 C]2 and [ 11 C]3 proved straightforward using standard O-methylation on the corresponding diphenol precursors (8, 9) with [ 11 C]CH 3 I in the presence of four equivalents of NaH in DMF. This can be attributed to the fact that the phenoxide group generated under basic conditions is a stronger nucleophile than the secondary amino group. Purification by reversed phase HPLC afforded [ 11 C]2 and [
11 C]3 with more than 98% radiochemical purity, free from starting precursors. The specific radioactivity was estimated by UV spectroscopy to be around 75 GBq/mmol at the end of synthesis. Although the reaction conditions have not been optimized, the averages 1.2 GBq of [ 11 C]2 and 1.6 GBq of [ 11 C]3 after a 10 min proton bombardment at a beam current of 15 mA were obtained at end of synthesis, respectively.
In vitro bindings were initially examined by incubating the rat brain slices in a Tris HCl buffer containing [ 11 C]2 or [ 11 C]3. As shown in Fig. 2 , the ratios regions to cerebellum, a region free of the NR2B subunit, for the two radioligands were almost unity in all brain regions tested (cerebral cortex, hippocampus, striatum, and thalamus), thus demonstrating almost homogeneous distribution throughout the brain. Nonspecific bindings of [ 11 C]2 and [ 11 C]3 were about 50% and 60% of total binding, respectively, in all brain regions, as determined by the presence of the corresponding 100 mM nonradioactive ligands (Fig. 3) . No significant difference in the bindings was observed between Tables 1 and 2 . Among the ligands examined, ifenprodil and spermine inhibited the in vitro bindings with potencies similar to those of non-radioactive 2 or 3 at the same 100 mM concentration. The highly potent NR2B-selective NMDA antagonist, CP-101,606, inhibited the binding of [ , respectively, at a 10 mM concentration. It is known that ifenprodil shows equal affinities to several other CNS receptors such as s-binding sites and a 1 -adrenergic receptors. 28, 29) The bindings of [ 11 C]2 and [ 11 C]3 to s-binding sites and a 1 -adrenergic receptors, however, were negligible by the fact that 100 mM s-and a-antagonists did not show significant inhibition for either the [ 11 C]2 or [ 11 C]3 bindings. Among the polyamines, spermine showed the most potent inhibition, followed by spermidine, while putrescine showed only 10-15% inhibition even at a 1 mM concentration. These orders of inhibitory effects by polyamines are similar to those reported for the inhibition of [ 3 H]CP-101,606 and [ 3 H]ifenprodil. [30] [31] [32] [33] Although the highaffinity ifenprodil site is supposed to be located on the NR2B subunit, a low-affinity ifenprodil site has also been proposed, through which ifenprodil acts as a weak open-channel blocker. 34) Divalent cations also inhibited the [ 11 C]2 at concentrations of 100 mM, whereas no inhibition of [ 11 C]3 was observed with these ligands at the same concentrations, suggesting that the binding of [ 11 C]2 was also occurring at the serotonin recognition sites. As shown in Figs. 2 and 3 , taking into account the bindings of the radioligands to the cerebellum, a region free of the NR2B subunit, it seems likely that these radioligands bind to the spermine-and/or ifenprodil-binding sites unrelated to the NR2B subunit. Our efforts to determine the IC 50 value from inhibition studies using rat brain slices have not been successful because of high nonspecific binding fractions, but bis(phenylalkyl)-amine 2 and 3 are estimated to have moderate affinities to the spermine-and/or ifenprodil-binding sites.
From these in vitro results, [ 11 C]3 was chosen for further evaluation under in vivo conditions because of its greater selectivity for the spermine-and/or ifenprodil-binding sites than [
11 C]2. The brain regional distribution of [ 11 C]3 after intravenous injection was investigated using mice. As shown in Table 3, [ 11 C]3 showed an initial moderate brain uptake (0.8-0.9% dose/g) and increased slightly with time. The radioactivity levels of blood were lower than those in the brain. No significant difference in the regional brain distribution was observed, similar to the in vitro brain distribution.
Furthermore, we evaluated the effect of pre-treatment with spermine or with non-radioactive 3 on brain uptake using rats. As shown in Fig. 4 , pre-treatment with non-radioactive 3 (7 mmol/kg) caused a statistically significant increase of radioactivity in the cerebral cortex and hippocampus compared with the control group. The reasons for this observation are uncertain in the present study. However, it is likely that the binding of [ 11 C]3 in peripheral binding sites or to plasma proteins might be prevented, resulting in an increased availability for uptake in the brain. Thus, this pre-treatment with unlabelled 3 suggests that the uptake observed is nonspecific in nature. Pre-treatment with spermine (7 mmol/kg) did not produce any change of uptake in the brain compared to the control. This finding is in contrast to the in vitro inhibition of [ 11 C]3 binding on brain slices. The insensitivity of a blocking effect by exogenously administered spermine is probably due to the low penetration of spermine across the blood-brain barrier, 36) and it is also feasible that a high concentration of endogenous polyamines, such as spermine, in the central nervous system would behave as an endogenous inhibitor for [
11 C]3 binding in vivo. Recently it has been proven that the In vivo brain distribution of [ 11 C]3 was further assessed by a conscious Rhesus monkey in conjunction with PET. Figure  5 shows the normalized time activity curves in the frontal and occipital cortex, and cerebellum for 90 min of PET scanning after intravenous injection of [ 11 C]3. The radioactivity reached maximal values at 20-30 min and then decreased slightly until the end of the experiments. No significant regional differences in uptake of radioactivity were observed, similar to what we obtained using mouse and rat brains, as described above. When unlabelled 3 (6 mmol/kg) was co-injected with [ 11 C]3, a slight decrease in brain radioactivity that was most apparent at later time-points, was induced as shown in Fig. 5 the NMDA receptors.
